- Home
- SLS
as of 12-03-2025 4:00pm EST
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 208.0M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $2.48 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered SLS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of SELLAS Life Sciences Group Inc. (SLS)
Director
Avg Cost/Share
$1.59
Shares
63,400
Total Value
$100,806.00
Owned After
104,400
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kalin Katherine Bach | SLS | Director | Nov 19, 2025 | Buy | $1.59 | 63,400 | $100,806.00 | 104,400 |
Compare SLS vs Leading Stocks
See how SLS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SLS SELLAS Life Sciences Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.